Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider transactions rather than a financial performance report.
Material Changes
On February 24, 2011, a connected person of Dr. M. M. Slaoui (a Person Discharging Managerial Responsibility) received an award of 2,450 ADSs under the 2009 Share Value Plan. The Company and the connected person were advised of these transactions on February 25, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADSs awarded to Dr. Slaoui's connected person (2,450).
- Confirm the specific plan under which the award was granted (2009 Share Value Plan).
- Note the transaction date (February 24, 2011) versus the notification date (February 25, 2011).